Neurological disorder

Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the second quarter ended June 30, 2023.
  • Net product revenue for the three months ended June 30, 2023 was $98.2 million, compared to net product revenue of $71.4 million for the three months ended March 31, 2023.
  • Financial Results for the Second Quarter Ended June 30, 2023
    For the three months ended June 30, 2023, net product revenue was $98.2 million, and cost of sales were $5.6 million.
  • Cash, cash equivalents, and short-term investments were $357.3 million at June 30, 2023, compared to $345.7 million at March 31, 2023.

Migraine: A common headache disorder that is underdiagnosed and undertreated

Retrieved on: 
Tuesday, August 1, 2023

However, even in Canada, with a universal health-care system, migraine is underdiagnosed and undertreated.

Key Points: 
  • However, even in Canada, with a universal health-care system, migraine is underdiagnosed and undertreated.
  • Policymakers need to act now to remove the barriers to accessing migraine medications in Canada, particularly as new medications are marketed.

What is migraine?

    • Pain typically affects one side of the head and presents with nausea or vomiting, sensitivity to light or sound and interference with routine physical activity.
    • Migraine can be episodic (fewer than 15 headache days per month) or chronic (15 or more headache days per month for longer than three months).

Impact of migraine

    • Migraine is associated with lost productivity and with other health conditions including asthma, epilepsy and cardiovascular disease.
    • Furthermore, migraine can contribute to mental health problems, including depression and anxiety.
    • Canada is no stranger to this trend, where migraine affects 4.7 per cent of men and 11.8 per cent of women each year.

Historically, migraine has been underdiagnosed

    • Factors influencing diagnosis include an individual’s ability and willingness to access care, and a physician identifying and correctly diagnosing migraine.
    • However, research has demonstrated that for chronic migraine, most individuals report consulting a physician about their headaches.
    • This suggests that in people with chronic migraine specifically, underdiagnosis may be driven by the failure to receive a correct diagnosis from a health-care provider.

Migraine-specific medications are under-used

    • Triptans are among the oldest migraine-specific medications, and the first-line treatment for migraine for those who do not get relief from over-the-counter medications.
    • Despite this, many individuals living with migraine in Canada do not use or have not tried migraine-specific medications.
    • As new migraine-specific medications are approved in Canada, it is important that those who need them can access these treatments.
    • These medications are used to prevent migrainous headaches, and cost over $600 per month.

Steps you can take if you think you might have migraine

    • Migraine Buddy is a migraine tracking app with a questionnaire to help individuals determine if they may have migraine and should discuss their symptoms with a physician.
    • Effective treatment options exist to manage migraine, which can be accessed through a physician.

American Parkinson Disease Association Launches Professional Training Course to Educate About Advanced Parkinson's Disease

Retrieved on: 
Monday, July 31, 2023

NEW YORK, July 31, 2023 /PRNewswire-PRWeb/ -- Parkinson's disease (PD) is a progressive neurological disorder and although the rate of progression varies significantly from person to person, progression itself is inevitable. With a mission to improve the quality of life of those living with PD, the American Parkinson Disease Association (APDA) created Taking Care of the Person with Advanced Parkinson's Disease©, a specialized online training course to help those who care for people with PD – particularly home health aides, nursing home staff, and visiting nurses – better understand the symptoms and challenges that come with advanced PD and how to best manage them.

Key Points: 
  • The goal of Taking Care of the Person with Advanced Parkinson's Disease is for those who complete the course to feel better equipped to handle the obstacles that may come their way when caring for someone with advanced PD.
  • The course presents an overview of Parkinson's disease, with a focus on the person with advanced PD and is divided into three sections:
    The basics of Parkinson's disease, including the motor symptoms of PD.
  • Taking Care of the Person with Advanced Parkinson's Disease is now one of three free online training courses for professionals created by APDA, all available at http://www.apdaparkinson.org/training .
  • APDA Parkinson's Disease Training for Fitness, Health & Wellness Professionals
    Parkinson's disease is the second-most common neurodegenerative disease (after Alzheimer's) with 90,000 new diagnoses in the United States every year.

Anuncia Medical Successfully Launches Second Generation Device to Treat Hydrocephalus at Several Leading Neurosurgical Centers Across the United States

Retrieved on: 
Wednesday, July 26, 2023

SCOTTSDALE, Ariz., July 26, 2023 /PRNewswire/ -- Anuncia Medical Inc. ("Anuncia" or the "Company"), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful U.S. commercial launch of the ReFlow™ Mini Flusher device. Neurosurgeons in the US and soon internationally will now have a new option to reduce the impact of hydrocephalus by providing better access to potentially life-saving therapy for the 30 million patients worldwide suffering from this neurological disorder. Hydrocephalus is a chronic neurological condition in which excess CSF accumulates in the brain, often causing severe symptoms, frequent hospitalizations, and ongoing health concerns, and may be fatal if left untreated.

Key Points: 
  • The just launched second-generation ReFlow Mini Flusher is FDA-cleared for use in patients living with hydrocephalus or similar conditions.
  • Its reduced size and profile  are designed to better support a broader hydrocephalus patient population, from infants to older adults.
  • Since the ReFlow Mini became available earlier this month, multiple leading centers across the country have successfully implanted the technology.
  • We share a common mission with leading neurosurgical and hydrocephalus organizations of improving access to better care and quality of life and providing peace of mind to patients.

Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand

Retrieved on: 
Thursday, July 20, 2023

‘‘We are pleased to expand our ongoing international roll-out of ZENEO® Midazolam to treat certain epileptic crisis into Australia and New Zealand, with this licensing agreement,” said Patrick Alexandre, CEO of Crossject.

Key Points: 
  • ‘‘We are pleased to expand our ongoing international roll-out of ZENEO® Midazolam to treat certain epileptic crisis into Australia and New Zealand, with this licensing agreement,” said Patrick Alexandre, CEO of Crossject.
  • There is a clear need for a simple and dependable needle-free way to administer an emergency treatment for epilepsy.
  • “We are very pleased to partner with Crossject to bring ZENEO® Midazolam to our core market,” said Dr Hartley Atkinson, CEO of AFT Pharmaceuticals.
  • AFT Pharmaceuticals Limited (ASX: AFP & NZX:AFT) is a specialty pharmaceutical company operating primarily in Australasia, but with product distribution agreements worldwide.

Parkinson's Foundation Invests $2.8 Million in Research Grants

Retrieved on: 
Tuesday, July 18, 2023

MIAMI and NEW YORK, July 18, 2023 /PRNewswire/ -- The Parkinson's Foundation has announced an investment of $2.8 million in 30 grants to accelerate cutting-edge Parkinson's disease (PD) research.

Key Points: 
  • MIAMI and NEW YORK, July 18, 2023 /PRNewswire/ -- The Parkinson's Foundation has announced an investment of $2.8 million in 30 grants to accelerate cutting-edge Parkinson's disease (PD) research.
  • Through research grants, the Foundation funds scientists conducting innovative studies across various aspects of PD to bring forward new therapies, treatments, and ultimately a cure for the 10 million people worldwide living with this debilitating neurological disease.
  • Parkinson's Foundation research grants are selected through a highly competitive application process that is comprised of a peer-review panel of scientific experts, including members of the Foundation's Scientific Advisory Board and Foundation-trained research advocates.
  • For a complete list of 2023 recipients and more information about Parkinson's Foundation research grant opportunities, please visit Parkinson.org/ResearchGrants .

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

Retrieved on: 
Monday, July 17, 2023

NEW ORLEANS and CHERRY HILL, N.J., July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary. The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders. The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers. These rights would terminate in the event the transaction is not consummated.

Key Points: 
  • The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders.
  • The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers.
  • The StemoniX microBrain technology is a highly scalable iPSC-derived high-throughput neural screening platform coupled with advanced bioanalytical software for phenotypic drug discovery.
  • "We believe that AxoSim is the perfect partner for our StemoniX microBrain technology," said Andrew LaFrence, President, Chief Executive Officer and Chief Financial Officer of Vyant Bio.

Neurologics Unveils Life-Changing Evaluation Center in Newport Beach, Empowering Individuals to Amplify Their Brain Power

Retrieved on: 
Tuesday, July 11, 2023

Harnessing the power of neuroengineering and spearheading breakthrough methodologies, Neurologics has shattered the boundaries of what's possible in brain optimization.

Key Points: 
  • Harnessing the power of neuroengineering and spearheading breakthrough methodologies, Neurologics has shattered the boundaries of what's possible in brain optimization.
  • We are committed to empowering individuals to unlock their true cognitive potential and embark on a journey towards lasting transformation."
  • The Neurologics Assessment Center in Newport Beach offers an extraordinary range of assessments and evaluations that go beyond conventional methods.
  • To embark on a life-changing journey to reclaim your optimal brain health, schedule your assessment at the Neurologics Assessment Center in Newport Beach today.

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Retrieved on: 
Friday, June 30, 2023

TEL AVIV, Israel, June 30, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its Phase IIb clinical trial to use SCI-110 for treating adults with Tourette Syndrome ("TS") at the Hannover Medical School in Hannover, Germany.

Key Points: 
  • The Company has already secured the Institutional Review Board (“IRB) approvals from all three clinical sites as well as the Israeli Ministry of Health's approval for the clinical trial at Sourasky.
  • "We are excited to announce that SciSparc has received another official approval to embark on its Phase IIb Clinical Trial for SCI-110, aimed at treating TS, in Germany.
  • This Phase IIb Clinical Trial will enable us to rigorously evaluate the safety and efficacy of SCI-110, and we believe will further solidify its potential as a game-changing therapy."
  • The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.

Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)

Retrieved on: 
Tuesday, June 13, 2023

It is the fourth most common neurological disorder worldwide.

Key Points: 
  • It is the fourth most common neurological disorder worldwide.
  • EPM7 symptoms typically emerge between the ages of 3 and 15, with progressively severe myoclonus, ataxia, and occasional tonic-clonic seizures.
  • Current anti-seizure drugs can help to reduce the incidence of tonic-clonic seizures, but these drugs do not improve the myoclonus or ataxia.
  • The Office of Orphan Products Development has also granted orphan drug designation for AUT00201 for the treatment of EPM7.